BCYC Bicycle Therapeutics
- 26.360
- +5.820+28.33%
- 26.200
- -0.160-0.61%
Bicycle Therapeutics News
ADRs Advance; Bicycle Therapeutics Ltd. Climbs 28%
Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $38
Express News | Cantor Fitzgerald Reiterates Overweight on Bicycle Therapeutics
Oppenheimer Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $48
Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
RBC Capital Initiates Bicycle Therapeutics(BCYC.US) With Buy Rating, Announces Target Price $35
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics (NASDAQ:BCYC) Shareholders Have Earned a 26% CAGR Over the Last Five Years
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
European Equities Traded in the US as American Depositary Receipts Open Week Strong Monday Trading
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
Bicycle Therapeutics: Buy Rating Affirmed on Strong Q2 Financials and Promising Pipeline Developments
The Latest Analyst Ratings For Bicycle Therapeutics
Bicycle Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Bicycle Therapeutics Cut at B. Riley Ahead of Data Readouts
Express News | Bicycle Therapeutics Shares Are Trading Lower After B. Riley Securities Downgraded the Stock From Buy to Neutral and Lowered Its Price Target From $33 to $28
Express News | Oppenheimer Maintains Outperform on Bicycle Therapeutics, Maintains $48 Price Target
Analysis
Price Target
No Data
